KR20240004205A - 방사성의약 및 방법 - Google Patents
방사성의약 및 방법 Download PDFInfo
- Publication number
- KR20240004205A KR20240004205A KR1020237004275A KR20237004275A KR20240004205A KR 20240004205 A KR20240004205 A KR 20240004205A KR 1020237004275 A KR1020237004275 A KR 1020237004275A KR 20237004275 A KR20237004275 A KR 20237004275A KR 20240004205 A KR20240004205 A KR 20240004205A
- Authority
- KR
- South Korea
- Prior art keywords
- lutetium
- iodo
- dotaga
- euk
- sub
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051335P | 2020-07-13 | 2020-07-13 | |
| US63/051,335 | 2020-07-13 | ||
| US202163143664P | 2021-01-29 | 2021-01-29 | |
| US63/143,664 | 2021-01-29 | ||
| PCT/IB2021/000467 WO2022013610A2 (en) | 2020-07-13 | 2021-07-13 | Radiopharmaceutical and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240004205A true KR20240004205A (ko) | 2024-01-11 |
Family
ID=79171978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237004275A Withdrawn KR20240004205A (ko) | 2020-07-13 | 2021-07-13 | 방사성의약 및 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11491246B2 (enExample) |
| EP (1) | EP4178628A4 (enExample) |
| JP (1) | JP2023539990A (enExample) |
| KR (1) | KR20240004205A (enExample) |
| AU (1) | AU2021309907A1 (enExample) |
| BR (1) | BR112023000763A2 (enExample) |
| CA (1) | CA3185565A1 (enExample) |
| IL (1) | IL299760A (enExample) |
| MX (1) | MX2023000623A (enExample) |
| TW (1) | TW202216205A (enExample) |
| WO (1) | WO2022013610A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12324846B2 (en) | 2023-07-31 | 2025-06-10 | Curium Us Llc | [177LU] lutetium-PSMA IandT composition and dosimetry, kit, method of making, and method of using thereof |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023539990A (ja) | 2020-07-13 | 2023-09-21 | ポイント バイオファーマ インコーポレイテッド | 放射性薬剤および方法 |
| WO2023164769A1 (en) * | 2022-03-02 | 2023-09-07 | Point Biopharma, Inc. | Radiopharmaceutical and methods |
| CN114404618A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其用途 |
| CN114404619A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| WO2023215333A1 (en) * | 2022-05-02 | 2023-11-09 | Point Biopharma, Inc. | Radiopharmaceutical and methods |
| CN115015441B (zh) * | 2022-07-14 | 2023-08-18 | 原子高科股份有限公司 | 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法 |
| EP4558178A2 (en) * | 2022-07-18 | 2025-05-28 | Curium US LLC | Radiopharmaceutical compositions of copper for targeted molecular imaging |
| WO2024151320A2 (en) * | 2022-07-29 | 2024-07-18 | Curium Us Llc | [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof |
| EP4568985A1 (en) * | 2022-08-11 | 2025-06-18 | Advancell Isotopes Pty Limited | Radiopharmaceuticals |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| IL319722A (en) | 2022-09-23 | 2025-05-01 | Nuclidium Ag | High purity radionuclides and their diagnostic and medical uses |
| EP4630063A1 (en) | 2022-12-05 | 2025-10-15 | Novartis AG | Method of treating prostate cancer |
| TW202506204A (zh) * | 2023-04-14 | 2025-02-16 | 加拿大商融合製藥公司 | Psma靶向放射性藥物及dna損傷反應抑制劑之組合療法 |
| EP4743125A1 (en) | 2023-07-11 | 2026-05-20 | Novartis AG | PROSTATE CANCER TREATMENT METHOD |
| EP4746926A2 (en) | 2023-07-21 | 2026-05-27 | Novartis AG | Psma-targeting radioligand treatment regimen |
| WO2025171492A1 (en) | 2024-02-14 | 2025-08-21 | Alpha-9 Oncology Inc. | Stable radiopharmaceutical compositions and uses thereof |
| WO2025235951A1 (en) * | 2024-05-09 | 2025-11-13 | Curium Us Llc | Radiopharmaceutical compositions for actinium in targeted radionuclide therapy |
| WO2026019453A1 (en) * | 2024-07-15 | 2026-01-22 | Curium Us Llc | [177lu]lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof |
| WO2026159621A1 (en) | 2025-01-23 | 2026-07-30 | Novartis Ag | Treatment regimen using psma-binding radioligands in combination with androgen receptor pathway inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2526760A1 (en) * | 2003-05-23 | 2005-01-06 | Epix Pharmaceuticals, Inc. | Optically pure and enriched isomers of chelating ligands and contrast agents |
| CN100418585C (zh) | 2003-07-24 | 2008-09-17 | 伯拉考成像股份公司 | 稳定的放射性药物组合物及制备方法 |
| WO2016149188A1 (en) | 2015-03-13 | 2016-09-22 | The Johns Hopkins University | 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| ES2743482T3 (es) | 2014-05-06 | 2020-02-19 | Univ Johns Hopkins | Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia |
| US10980901B2 (en) | 2016-12-15 | 2021-04-20 | The European Atomic Energy Community (Euratom), Represented By The European Commission | Treatment of PMSA expressing cancers |
| US11478558B2 (en) | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| US10596276B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
| US20200030466A1 (en) * | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) Srl | Stable, concentrated radionuclide complex solutions |
| AU2019345320B2 (en) | 2018-09-21 | 2025-12-11 | Endocyte, Inc. | Methods of treating cancer |
| WO2020064693A1 (en) | 2018-09-25 | 2020-04-02 | Advanced Accelerator Applications (Italy) Srl | Combination therapy |
| WO2020157177A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
| JP2023539990A (ja) | 2020-07-13 | 2023-09-21 | ポイント バイオファーマ インコーポレイテッド | 放射性薬剤および方法 |
| US11129912B1 (en) * | 2020-07-13 | 2021-09-28 | POINT Biopharma Inc. | Radiopharmaceutical and methods |
| CN116528904A (zh) | 2020-08-27 | 2023-08-01 | 普罗博开发商业中心 | 放射性药物和方法 |
| WO2022111800A1 (en) | 2020-11-25 | 2022-06-02 | Itm Solucin Gmbh | Stable formulations for radionuclide complexes |
| WO2023097329A1 (en) | 2021-11-29 | 2023-06-01 | Point Biopharma, Inc. | Radiopharmaceutical treatment methods and use |
-
2021
- 2021-07-13 JP JP2023502702A patent/JP2023539990A/ja not_active Ceased
- 2021-07-13 TW TW110125666A patent/TW202216205A/zh unknown
- 2021-07-13 WO PCT/IB2021/000467 patent/WO2022013610A2/en not_active Ceased
- 2021-07-13 IL IL299760A patent/IL299760A/en unknown
- 2021-07-13 US US17/374,984 patent/US11491246B2/en active Active
- 2021-07-13 BR BR112023000763A patent/BR112023000763A2/pt not_active Application Discontinuation
- 2021-07-13 KR KR1020237004275A patent/KR20240004205A/ko not_active Withdrawn
- 2021-07-13 CA CA3185565A patent/CA3185565A1/en active Pending
- 2021-07-13 EP EP21841476.1A patent/EP4178628A4/en active Pending
- 2021-07-13 MX MX2023000623A patent/MX2023000623A/es unknown
- 2021-07-13 AU AU2021309907A patent/AU2021309907A1/en active Pending
- 2021-09-27 US US17/486,875 patent/US20220016274A1/en not_active Abandoned
-
2022
- 2022-09-22 US US17/934,450 patent/US20230302163A1/en active Pending
-
2023
- 2023-04-17 US US18/135,595 patent/US12558440B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12324846B2 (en) | 2023-07-31 | 2025-06-10 | Curium Us Llc | [177LU] lutetium-PSMA IandT composition and dosimetry, kit, method of making, and method of using thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4178628A2 (en) | 2023-05-17 |
| WO2022013610A3 (en) | 2022-03-17 |
| MX2023000623A (es) | 2023-04-27 |
| US20240108765A1 (en) | 2024-04-04 |
| US20220016274A1 (en) | 2022-01-20 |
| TW202216205A (zh) | 2022-05-01 |
| IL299760A (en) | 2023-03-01 |
| CA3185565A1 (en) | 2022-01-20 |
| EP4178628A4 (en) | 2025-04-02 |
| WO2022013610A2 (en) | 2022-01-20 |
| AU2021309907A1 (en) | 2023-03-02 |
| JP2023539990A (ja) | 2023-09-21 |
| US12558440B2 (en) | 2026-02-24 |
| US11491246B2 (en) | 2022-11-08 |
| US20230302163A1 (en) | 2023-09-28 |
| US20220008564A1 (en) | 2022-01-13 |
| BR112023000763A2 (pt) | 2023-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12558440B2 (en) | Radiopharmaceutical and methods | |
| US11129912B1 (en) | Radiopharmaceutical and methods | |
| KR20220107020A (ko) | Erk 억제제로서 작용하는 스피로 화합물 및 이의 응용 | |
| US11439714B2 (en) | Radiopharmaceutical and methods | |
| US20250127940A1 (en) | Radiopharmaceutical and methods | |
| ES2616045T3 (es) | Forma estabilizada de tetrofosmina y su uso | |
| DK1901783T3 (en) | GENTIC ACID FOR STABILIZING 123-I RADIO PHARMACEUTICALS | |
| CN116547007A (zh) | 放射性药物和方法 | |
| US20240024519A1 (en) | Radiopharmaceutical compositions of copper for targeted molecular imaging | |
| EA008195B1 (ru) | Применение тория-227 в лучевой терапии заболеваний мягких тканей | |
| CN103153349A (zh) | 用于治疗人类肝癌的基于铼-188的组合物和制备这种组合物的方法 | |
| WO2023164769A9 (en) | Radiopharmaceutical and methods | |
| CN118742332A (zh) | 放射性药物和方法 | |
| HK40088578A (en) | Radiopharmaceutical and methods | |
| WO2021108474A1 (en) | Method for extraction and purification of ai18f-labeled hbed conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| B11 | Application withdrawn |
Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |